- Filament Health (FH) has signed a licensing agreement with ATMA Journey Centers
- Filament has licensed PEX010 (25mg), a naturally-extracted botanical drug candidate, to ATMA for use in clinical trials
- ATMA is striving to bring psychedelic-assisted therapy to the clinic
- Filament Health (FH) is an exclusively-natural psychedelic drug discovery and extraction technology company
- Filament Health Corp. (FH) opened trading at C$0.16 on the NEO Exchange
Filament Health (FH) has signed a licensing agreement with ATMA Journey Centers.
ATMA is Canada’s first private therapy company to conduct legal psilocybin therapy through the Health Canada Section 56 Exemption, assisting Canadians facing end-of-life distress from a terminal illness.
Under the agreement, Filament has licensed PEX010 (25mg), a naturally-extracted botanical drug candidate, to ATMA for use in clinical trials. This includes a phase I psilocybin safety trial in healthy individuals enrolled in a psychedelic-assisted therapy training program, for which ATMA recently received Health Canada approval.
“The selection of our natural psilocybin drug candidate for ATMA’s future clinical trials is a validation of both our product and the ease of working with Filament Health,” said Filament Chief Executive Officer, Benjamin Lightburn.
“ATMA is a leader in psychedelic-assisted psychotherapy and we are thrilled that they will be using our product,” he added.
David Harder, Co-Chief Executive Officer at ATMA remarked on the agreement.
“Filament’s candidate was an attractive option because they are a licensed manufacturer and their drug candidate has received approval from Health Canada to enter into multiple human clinical trials. We are proud to support a thriving domestic psychedelics industry by selecting Filament’s natural, Canadian-made drug candidate for future studies.”
ATMA is striving to bring psychedelic-assisted therapy to the clinic. ATMA and Filament Health believe the best way this is achieved is through clinical trials, demonstrating both safety and efficacy, for a variety of mental health indications.
Filament Health (FH) is an exclusively-natural psychedelic drug discovery and extraction technology company.
Filament Health Corp. (FH) opened trading at C$0.16 on the NEO Exchange.
